Celldex Therapeutics, Inc.
CLDX
$21.85
-$0.083-0.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.04% | -40.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.04% | -40.85% | |||
| Cost of Revenue | 3.01% | 12.09% | |||
| Gross Profit | -2.98% | -13.45% | |||
| SG&A Expenses | -3.96% | 5.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.82% | 10.89% | |||
| Operating Income | -1.78% | -11.98% | |||
| Income Before Tax | -5.21% | -14.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.21% | -14.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.21% | -14.24% | |||
| EBIT | -1.78% | -11.98% | |||
| EBITDA | -1.80% | -12.07% | |||
| EPS Basic | -5.19% | -14.19% | |||
| Normalized Basic EPS | -5.19% | -14.18% | |||
| EPS Diluted | -5.19% | -14.19% | |||
| Normalized Diluted EPS | -5.19% | -14.18% | |||
| Average Basic Shares Outstanding | 0.01% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.01% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||